Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy

Marieke A. de Graaff(Leiden University Medical Center), Judith V.M.G. Bovée(Leiden University Medical Center), Adrián Mariño‐Enríquez(Harvard University Press), Anne‐Marie Cleton-Jansen(Leiden University Medical Center), Frédéric Chibon(Centre National de la Recherche Scientifique), Marije A. J. de Rooij(Leiden University Medical Center), Jean‐Michel Coindre(Université de Bordeaux), Brendy E.W.M. van den Akker(Leiden University Medical Center), Jonathan A. Fletcher(Harvard University), Hans Gelderblom(Leiden University Medical Center)
British Journal of Cancer
May 1, 2016
10.1038/bjc.2016.117
Cited by 19

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k